scholarly journals First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series

2021 ◽  
Vol 12 (11) ◽  
pp. 1037-1046
Author(s):  
Sebastiano Buti ◽  
Melissa Bersanelli ◽  
Francesco Massari ◽  
Ugo De Giorgi ◽  
Orazio Caffo ◽  
...  
Keyword(s):  
Renal Carcinoma ◽  
Clear Cell ◽  
Case Series ◽  
Clear Cell Renal Carcinoma ◽  
First Line ◽  
Italian Case ◽  
Cell Renal Carcinoma

scholarly journals First-line PAzopanib in NOn-clear cell Renal cArcinoMA: the Italian retrospective multicenter PANORAMA study

2016 ◽  
Vol 27 ◽  
pp. vi290 ◽  
Author(s):  
M. Bersanelli ◽  
F. Maines ◽  
G. Facchini ◽  
F. Gelsomino ◽  
F. Zustovich ◽  
...  
Keyword(s):  
Renal Carcinoma ◽  
Clear Cell ◽  
Clear Cell Renal Carcinoma ◽  
First Line ◽  
Cell Renal Carcinoma

scholarly journals Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review

2020 ◽  
Vol 12 ◽  
pp. 175883592091530
Author(s):  
Melissa Bersanelli ◽  
Matteo Brunelli ◽  
Letizia Gnetti ◽  
Umberto Maestroni ◽  
Sebastiano Buti
Keyword(s):  
Systematic Review ◽  
Renal Carcinoma ◽  
Clear Cell ◽  
Therapeutic Option ◽  
Comparable Efficacy ◽  
Line Treatment ◽  
Clear Cell Renal Carcinoma ◽  
First Line ◽  
Cell Renal Carcinoma ◽  
First Line Treatment

Background: Effective systemic treatment of non-clear cell renal carcinoma (nccRCC) is still an unmet clinical need, with few studies to support an evidence-based approach. To date, the only recommended standard first-line treatment is sunitinib. Pazopanib may also be used in nccRCC but its place in therapy is not clearly established. It has comparable efficacy and better tolerability than sunitinib in clear cell renal carcinoma. Our objective was to review the use of pazopanib in metastatic nccRCC. Methods: We conducted a systematic review according to PRISMA guidelines. Any type of study reporting the use of pazopanib in metastatic renal cell carcinoma including cases with non-clear cell histology was eligible. Results: In all, 15 studies were included in our analysis, including a total of 318 nccRCC patients treated with pazopanib. Most studies were retrospective ( n = 12); three were prospective trials. The specific outcomes of nccRCC patients were reported by four studies. Pazopanib alone as first-line treatment gave overall response rates ranging from 27% to 33%, disease control rates of 81–89%, median progression free survival of 8.1–16.5 months and median overall survival of 17.3–31.0 months. Grade 3–4 adverse events rates were 21–55%. Conclusion: The present review provides for the first time a systematic summary of evidence about the possible use of pazopanib as first-line treatment for nccRCC, with a favorable outcome despite the low strength of evidence. Pazopanib could be considered as a possible therapeutic option in this setting.

scholarly journals First-line PAzopanib in NOn-clear cell Renal cArcinoMA: the Italian retrospective multicenter PANORAMA study

2016 ◽  
Vol 27 ◽  
pp. iv32
Author(s):  
M. Bersanelli ◽  
F. Maines ◽  
G. Facchini ◽  
F. Gelsomino ◽  
F. Zustovich ◽  
...  
Keyword(s):  
Renal Carcinoma ◽  
Clear Cell ◽  
Clear Cell Renal Carcinoma ◽  
First Line ◽  
Cell Renal Carcinoma

First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study

2017 ◽  
Vol 15 (4) ◽  
pp. e609-e614 ◽  
Author(s):  
Sebastiano Buti ◽  
Melissa Bersanelli ◽  
Francesca Maines ◽  
Gaetano Facchini ◽  
Francesco Gelsomino ◽  
...  
Keyword(s):  
Renal Carcinoma ◽  
Clear Cell ◽  
Clear Cell Renal Carcinoma ◽  
First Line ◽  
Cell Renal Carcinoma

First-line pazopanib in non-clear cell renal carcinoma: The Italian retrospective multicenter PANORAMA study.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e16081-e16081 ◽  
Author(s):  
Sebastiano Buti ◽  
Melissa Bersanelli ◽  
Francesca Maines ◽  
Gaetano Facchini ◽  
Francesco Gelsomino ◽  
...  
Keyword(s):  
Renal Carcinoma ◽  
Clear Cell ◽  
Clear Cell Renal Carcinoma ◽  
First Line ◽  
Cell Renal Carcinoma

1651: Molecular Prognostic Modeling Using Protein Expression Profile in Clear Cell Renal Carcinoma

2004 ◽  
Vol 171 (4S) ◽  
pp. 436-436 ◽  
Author(s):  
Hyung L. Kim ◽  
David B. Seligson ◽  
Nicolette Janzen ◽  
Matthew H. Bui ◽  
Robert A. Figlin ◽  
...  
Keyword(s):  
Protein Expression ◽  
Expression Profile ◽  
Renal Carcinoma ◽  
Clear Cell ◽  
Clear Cell Renal Carcinoma ◽  
Protein Expression Profile ◽  
Cell Renal Carcinoma ◽  
Prognostic Modeling

scholarly journals The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma

Oncogene ◽  
2007 ◽  
Vol 26 (45) ◽  
pp. 6499-6508 ◽  
Author(s):  
J S P Yuen ◽  
M E Cockman ◽  
M Sullivan ◽  
A Protheroe ◽  
G D H Turner ◽  
...  
Keyword(s):  
Tumor Suppressor ◽  
Renal Carcinoma ◽  
Clear Cell ◽  
Clear Cell Renal Carcinoma ◽  
Cell Renal Carcinoma

scholarly journals The Influence of the Extremely Low Frequency Electromagnetic Field on Clear Cell Renal Carcinoma

2021 ◽  
Vol 22 (3) ◽  
pp. 1342
Author(s):  
Aleksandra Cios ◽  
Martyna Ciepielak ◽  
Wanda Stankiewicz ◽  
Łukasz Szymański
Keyword(s):  
Electromagnetic Field ◽  
Cancer Cells ◽  
Cell Lines ◽  
Renal Carcinoma ◽  
Clear Cell ◽  
Low Frequency ◽  
Inhibitory Effect ◽  
Hek293 Cells ◽  
Clear Cell Renal Carcinoma ◽  
Cell Renal Carcinoma

The development of new technologies and industry is conducive to the increase in the number and variety of electromagnetic field (EMF) sources in our environment. The main sources of EMF are high-voltage lines, household appliances, audio/video devices, mobile phones, radio stations, and radar devices. In the growing use of electronic devices, scientists are increasingly interested in the effects of EMF on human health. Even though many studies on the effects of EMF have already been carried out, none of them has shown a significant effect on mammals, including humans. Moreover, it is not entirely clear how EMF influences cell behavior. The International Agency for Research on Cancer on 31 May 2011, classified PEM as a possible carcinogenic factor. This study aimed to investigate the effect of the electromagnetic field on morphological and functional changes in clear cell renal carcinoma. The research was carried out on in vitro cultures of four cell lines: HEK293, 786-O 769-P, and Caki1. The results of the research showed that the EMF of low frequency had a slight effect on the viability of cells. EMF, which induced cell arrest in the G1 phase, increased the number of early apoptotic cells and decreased the number of viable cells in the 786-O line. EMF did not affect the proliferation and viability of HEK293 cells. Extreme low-frequency EMF (ELF-EMF) also showed an inhibitory effect on the migration and metastatic properties of clear cell kidney cancer cells. Moreover, shortly after the end of ELF-EMF exposure, significant increases in ROS levels were observed in all tested cell lines. As part of the work, it was shown that low-frequency EMF shows an inhibitory effect on the proliferation of primary cancer cells, diminishing their migratory, invasive, and metastatic abilities. It also increases the apoptosis of cancer cells and the amount of reactive oxygen species. Based on the results of our research, we want to point up that the effect of ELF-EMF depends on a specific metabolic state or at a specific stage in the cell cycle of the cells under study.

A combined postoperative nomogram for survival prediction in clear cell renal carcinoma

2021 ◽  
Author(s):  
Ying Ming ◽  
Xinyi Chen ◽  
Jingxu Xu ◽  
Haiyu Zhan ◽  
Jie Zhang ◽  
...  
Keyword(s):  
Renal Carcinoma ◽  
Clear Cell ◽  
Survival Prediction ◽  
Clear Cell Renal Carcinoma ◽  
Cell Renal Carcinoma

scholarly journals TNIP1 Inhibits Proliferation And Promotes Apoptosis In Clear Cell Renal Carcinoma Through Targeting C/Ebpβ

2019 ◽  
Vol Volume 12 ◽  
pp. 9861-9871
Author(s):  
Yong Yang ◽  
Jinhai Fan ◽  
Shenglu Han ◽  
Enyuan Li
Keyword(s):  
Renal Carcinoma ◽  
Clear Cell ◽  
Clear Cell Renal Carcinoma ◽  
Cell Renal Carcinoma
Sign in / Sign up

Export Citation Format

Share Document